Inhibitory activity of fluticasone propionate (FP) and salmeterol (SAL) on TGF-β–induced expression of α-smooth muscle actin (α-SMA) by human primary airway fibroblasts (Fbs) Source: Annual Congress 2003 - Cell signalling and cytokines in asthma Year: 2003
COPD: Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination and oxygen saturation (OS) in patients (pts) with different plasma surfactant protein D (SP-D) level Source: International Congress 2015 – COPD: notable points Year: 2015
Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
Platelet activating factor receptor (PAFr) expression is increased in airways of COPD patients but is not attenuated by inhaled corticosteroid (ICS) Source: Annual Congress 2013 –COPD: new markers of diseases Year: 2013
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
E-cadherin (CDH-1 ) polymorphisms associate with airway remodeling, inflammation and FEV1 decline in asthma patients using inhaled corticosteroids (ICS) Source: Annual Congress 2010 - The impact of genes and environment on obstructive airway diseases Year: 2010
Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Lack of effect of promoter, coding and 3‘ polymorphisms of the β2 -adrenergic receptor (ADRB2 ) on the clinical response to salmeterol alone or with fluticasone propionate in subjects with asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
The influence of polymorphisms of the β2 - adrenoceptor (AR) gene and the β2 -AR upstream peptide (BUP) on bronchoprotective tolerance development in asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 515s Year: 2001
Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
ADRB2R gene polymorphism (pol.) associated with the severity of cystic fibrosis(CF) and the effectiveness of the use of inhaled bronchodilator Source: Annual Congress 2010 - Cystic fibrosis: clinical and laboratory studies Year: 2010
Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Inhaled corticosteroids (ICS) attenuates epithelial mesenchymal transition (EMT) in COPD: A key to understanding long term benefits? Source: Annual Congress 2012 - Basic and translational studies in COPD Year: 2012
Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi Source: Eur Respir J 2007; 29: 575-581 Year: 2007
Anti-inflammatory effect of the combination of a long acting beta2-agonist (salmeterol) and a corticosteroid (fluticasone propionate) on human airway epithelial cells following Staphylococcus aureus infection Source: Eur Respir J 2005; 26: Suppl. 49, 98s Year: 2005
The inhibitory activity of fluticasone propionate (FP) on human bronchial epithelial cell (HBECs) functions in vitro is related to the intensity of the target cell response to stimuli (FLIC 24) Source: Eur Respir J 2002; 20: Suppl. 38, 91s Year: 2002
Salmeterol/fluticasone combination (SFC) is associated with improved asthma control compared with concurrent long-acting β2 agonists (LABA) and inhaled corticosteroids (ICS) or ICS alone Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA) Source: Eur Respir J 2005; 26: Suppl. 49, 717s Year: 2005